Skip navigation
Por favor, use este identificador para citar o enlazar este ítem:
Título: Odanacatib: a possible new therapeutic option for the treatment of osteoporosis
Autor: Pérez Castrillón, José Luis
Pinacho, Florentino
Ruiz Mambrilla, Marta
Dueñas Laita, Antonio
Año del Documento: 2012
Editorial: Future Medicine
Descripción: Producción Científica
Documento Fuente: International Journal of Clinical Rheumatology, vol. 7, n. 4, p. 1-8
Resumen: Cathepsin K is a protease released by osteoclasts, which is involved in the destruction of collagen fibers that form the organic phase of the bone matrix, and plays a key role in bone resorption. Odanacatib is a selective inhibitor of cathepsin K, which blocks bone remodeling by inhibiting resorption. Phase II trials have shown that odanacatib is a potent antiresorptive agent and does not significantly reduce biochemical markers of bone formation during long-term treatment of postmenopausal women. This increases the bone mineral density that is comparable with the most powerful antiresorptive agents. Odanacatib has a generally favorable tolerability and safety profile. Currently, only Phase II studies have been reported and its efficacy in reducing fractures has not been demonstrated. The adverse effects are reversible and disappear after discontinuation. If this antifracture efficacy can be shown, odanacatib could be a a safe, efficacious option for the treatment of osteoporosis.
Materias (normalizadas): Osteoporosis
ISSN: 1758-4272
Revisión por Pares: SI
Idioma: eng
Derechos: info:eu-repo/semantics/embargoedAccess
Aparece en las colecciones:DEP52 - Artículos de revista

Ficheros en este ítem:
Fichero Descripción TamañoFormato 
CASTRILLON 18[1].pdfPD-911,87 MBAdobe PDFThumbnail

Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons

Universidad de Valladolid
Powered by MIT's. DSpace software, Version 5.5